The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2360 views | HTML 3162 views | ?
Yunyan Gu1,*, Mengmeng Zhang1,*, Fuduan Peng1, Lei Fang4, Yuanyuan Zhang1, Haihai Liang3, Wenbin Zhou1, Lu Ao1,2 and Zheng Guo1,2
1 College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China
2 Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Department of Bioinformatics, Fujian Medical University, Fuzhou, China
3 Department of Pharmacology, Harbin Medical University, Harbin, China
4 Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Harbin Medical University, Harbin, China
* These authors contributed equally to this work
Zheng Guo, email:
Yunyan Gu, email:
Keywords: miRNAs, BRCA1, BRCA2, Prognosis, Ovarian Cancer
Received: October 23, 2014 Accepted: December 10, 2014 Published: December 11, 2014
Ovarian cancer patients carrying alterations (i.e., germline mutations, somatic mutations, hypermethylations and/or deletions) of BRCA1 or BRCA2 (BRCA1/2) have a better prognosis than BRCA1/2 alteration non-carriers. However, patients with wild-type BRCA1/2 may also have a favorable prognosis as a result of other mechanisms that remain poorly elucidated, such as the deregulation of miRNAs. We therefore sought to identify BRCA1/2-directed miRNA signatures that have prognostic value in ovarian cancer patients with wild-type BRCA1/2 and study how the deregulation of miRNAs impacts the prognosis of patients treated with platinum-based chemotherapy. By analyzing multidimensional datasets of ovarian cancer patients from the TCGA data portal, we identified three miRNAs (hsa-miR-146a, hsa-miR-148a and hsa-miR-545) that target BRCA1/2 and were associated with overall survival and progression-free survival in patients with wild-type BRCA1/2. By analyzing the expression profiles and Gene Ontology functional enrichment, we found that carriers of BRCA1/2 alterations and patients with miRNA deregulation shared a common mechanism, regulation of the DNA repair-related pathways, that affects the prognosis of ovarian cancer patients. Our work highlights that a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.